-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Accendra Health, Raises Price Target to $4.5

Benzinga·05/12/2026 22:12:57
Listen to the news
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.